Picard Medical Patient Achieves 2,900 Days with SynCardia Total Artificial Heart
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Source: Newsfilter
- Historic Milestone: Picard Medical announces that a patient has lived over 2,900 days with the SynCardia Total Artificial Heart, setting a world record that underscores the technology's significance and effectiveness for heart failure patients.
- Patient Background: This 46-year-old patient received the implant on December 9, 2017, at IVDK Dedinje Hospital in Serbia, and continues to live at home with family, showcasing the long-term support capabilities of the device.
- Clinical Success: Serbia's IVDK Dedinje Hospital leads globally with five patients supported for extended durations, reflecting the expertise of the cardiac surgical teams and their commitment to patient care.
- Future Development: Picard Medical is developing the next generation of fully implantable artificial heart systems, named “Emperor,” aimed at broadening treatment options and enhancing flexibility and accessibility for long-term support worldwide.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
